Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | PLAT | P00750 | 2/20 | 0.48 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 4/20 | 0.42 |
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL2980010 | 0.99 | MEN1 (0.51) | MEN1KMT2APLATHPGDSCHRNA7 | |
| SCHEMBL19399117 | 0.89 | CHRNA7 (0.50) | MEN1KMT2ACHRNA7MAOAMAOB | |
| Trifluoroacetic Acid SCHEMBL17766749 | 0.89 | PLAT (0.44) | MEN1KMT2APLATHPGDSCHRNA7 | |
| SCHEMBL4261351 | 0.86 | MEN1 (0.43) | MEN1KMT2APLATGABRA1GABRB2 | |
| SCHEMBL2299776 | 0.85 | CHRNA7 (0.47) | MEN1KMT2ACHRNA7MAOAMAOB | |
| Bromide SCHEMBL2987429 | 0.85 | MEN1 (0.43) | MEN1KMT2APLATGABRA1GABRB2 | |
| SCHEMBL13158408 | 0.84 | MEN1 (0.54) | MEN1KMT2AHPGDSGABRA1GABRB2 | |
| Hydrochloric Acid SCHEMBL3104691 | 0.82 | MEN1 (0.52) | MEN1KMT2AHPGDSGABRA1GABRB2 | |
| SCHEMBL28750361 | 0.79 | SLC6A4 (0.50) | MEN1KMT2AHTR2CNPC1RAB9A | |
| SCHEMBL3658790 | 0.79 | MEN1 (0.52) | MEN1KMT2APLATHPGDSGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771357-B2 | ALXR agonist compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-09-26 | — | — | US | disclosed |
| US-9771357-B2 | ALXR agonist compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-09-26 | — | — | US | disclosed |
| US-20160145249-A1 | ALXR AGONIST COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-05-26 | — | — | US | disclosed |
| US-20160145249-A1 | ALXR AGONIST COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-05-26 | — | — | US | disclosed |
| US-9334269-B2 | Carboxamides as inhibitors of voltage-gated sodium channels | AMGEN INC. (US) | 2016-05-10 | — | — | US | disclosed |
| WO-2015005305-A1 | ALXR AGONIST COMPOUND | 小野薬品工業株式会社 (JP) | 2015-01-15 | — | — | WO | disclosed |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2536689-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | Amgen Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011103196-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | AMGEN INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| EP-1945635-B1 | THIAZOLYL PIPERIDINE DERIVATIVES USEFUL AS H3 RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2009-05-06 | — | — | EP | disclosed |
| CN-101243078-A | Thiazolyl piperidine derivatives useful as h3 receptor modulators | HOFFMANN LA ROCHE (CH) | 2008-08-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | CACNA1B, SCN1A, CACNA1I | MEN1 3476/4885KMT2A 1099/4885PLAT 4543/4885 |
| US-20160145249-A1 | ALXR AGONIST COMPOUND | MRGPRX2, MRGPRX1, MRGPRX4 | MEN1 4744/4885KMT2A 2119/4885PLAT 2259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.